ARS Pharmaceuticals (SPRY) said Monday it submitted a supplemental new drug application to the US Food and Drug Administration for its needle-free neffy 1 mg treatment of type 1 allergic reactions in children weighing 15 to 30 kilograms.
The FDA has recently approved neffy 2 mg for the treatment of type 1 allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kg, the company said.
Shares of ARS Pharmaceuticals were more than 4% higher in after-hours activity.
Price: 12.23, Change: +0.52, Percent Change: +4.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments